A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Teprasiran (Primary)
- Indications Acute kidney injury
- Focus Registrational; Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 22 Oct 2018 According to a Quark Pharmaceuticals media release,data from this study will be presented at ASN 2018 and AAO 2018 Annual Meetings.
- 09 Jul 2018 According to a Quark Pharmaceuticals media release, first patient has been dosed.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.